A Marker Predicting Distant Metastasis (Spread) in Breast Cancer: IL-6

Researchers found that the inflammatory cytokine (a biological marker of inflammation ) known as interleukin-6(IL-6) may, in patients treated for stage 2 and 3 HER2-negative breast cancer, help predict whether their cancer will recur with metastasis by serving as a biomarker for that recurrence.
What is IL-6?
Interleukin-6 (IL-6) is a protein made by leukocytes (white blood cells) and other cells in the body, and is a type of cytokine.
Interleukin-6 is mainly made by certain T lymphocytes. When secreted, it causes B lymphocytes to produce more antibodies, and also causes fever by affecting the regions of the brain that control body temperature.
Laboratory-made, or synthetic, interleukin-6 is used as a biological response modifier to strengthen the immune system in cancer treatment. Conversely, drugs that block IL-6 are being tested in some diseases to calm an abnormal immune response, one of which is Covid-19. In conclusion, interleukin-6 is a type of cytokine with key roles in the functioning of the immune system. However, the roles of IL-6 are not limited to this; it has important functions in many metabolic and physiological processes in the body.
IL-6 in predicting breast cancer metastasis
Estrogen receptor (ER)-positive breast cancer was studied in a case-control study of 498 women treated with surgery and adjuvant chemotherapy, as well as endocrine (hormone-suppressing) therapies. Women with higher serum IL-6 levels at diagnosis, compared with women with lower levels, had a significantly higher risk of disease recurrence according to the findings.
At the ASCO 2021 Annual Meeting, these results were described as follows: "In high-risk stage II-III breast cancer, this provides level 1B (strong) evidence that higher levels at diagnosis of the cytokine IL-6 are associated with a significantly higher risk of distant recurrence despite optimal adjuvant systemic therapy".
Dr. Sparano, who presented the study, also stated that their findings needed to be confirmed in a larger study.
"Once confirmed, I think the other important issue is trying to understand what the best IL-6 cut-off point is for identifying high risk" he said.
A new target
Sparano and colleagues stated that knowledge is growing that systemic inflammation is a contributing factor in cancer progression and disease recurrence.
If further studies confirm that higher IL-6 levels are prognostic (predictive of disease course) for worse outcomes, it may be possible to use cytokine levels as a biomarker to predict therapies targeting the IL-6/Janus kinase/STAT3 pathway.
"There are ongoing clinical trials testing IL-6 antibodies in combination chemotherapy, and this could be a rational biomarker to identify which patients would be more likely to benefit from this approach" he said.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.